Talk:Pegaptanib
Appearance
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Pegaptanib.
|
Discovery by Gilead Disputed
[edit]I believe that it was actually NeXstar (founded by Larry Gold and Craig Tuerk) was the original discoverer. As Gilead didn't acquire NeXstar until 1999 -- a decade after Gold and Tuerk's work -- they shouldn't be credited.
http://www.epo.org/learning-events/european-inventor/finalists/2006/Gold.html
Daen (talk) 00:32, 4 June 2013 (UTC)
Patent expiry
[edit]US patents 6,113,906 and 5,919,455 on pegaptanib sodium expired around end October 2013. US patents 6,051,698, and 6,011,020, expire in 2015, & 2017. - Rod57 (talk) 06:20, 12 September 2015 (UTC)
- US patent 5,932,462 expired Aug 3, 2016. - Rod57 (talk) 09:14, 4 August 2016 (UTC)
Strange results from 2 'identical' phase 3 trials
[edit]It says the two phase 3 studies were identical but the 2nd year results are very different. What explanations have been given ? - Rod57 (talk) 09:11, 4 August 2016 (UTC)